<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901069</url>
  </required_header>
  <id_info>
    <org_study_id>07-NHL-06-UK/CC</org_study_id>
    <nct_id>NCT00901069</nct_id>
    <nct_alias>NCT00589160</nct_alias>
  </id_info>
  <brief_title>Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma</brief_title>
  <official_title>Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shams Shakil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, prospective, open label, dose escalation study of azacitidine in
      combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory
      lymphoma. The investigators expect to enroll 12-24 patients in this trial over a 2 year
      accrual period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximal tolerated dose (MTD) of azacitidine in combination with rituximab, vincristine, and cyclophosphamide in patients with lymphoma</measure>
    <time_frame>Eight 21 day cycles</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Azacitidine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine with rituximab, vincristine, and cyclophosphamide</intervention_name>
    <description>Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2^ Azacitidine 50 mg/m2^ Azacitidine 75 mg/m2^ Azacitidine 100 mg/m2^</description>
    <arm_group_label>Azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient or their authorized legally acceptable representative must consent to be in
             the study and must have signed and dated an approved consent form which conforms to
             federal and institutional guidelines.

          2. Age â‰¥ 18 years and without a maximum age.

          3. All patients of reproductive potential should not plan on conceiving children during
             the treatment program and must agree to use a medically accepted form of
             contraception.

          4. Women of childbearing potential must have a negative serum pregnancy test within 2
             weeks of beginning treatment.

          5. Patients must have relapsed lymphoma.

          6. ECOG performance status of 2 or better.

        Exclusion Criteria:

          1. Pregnant or breast-feeding at the time of proposed study entry

          2. Clinical AIDS or ARS or known positive HIV serology

          3. History of malignant neoplasm, other than lymphoma, treated within two years prior to
             study entry (other than non-melanoma skin cancer or in situ cervical cancer) or where
             there is current evidence of recurrent or metastatic disease

          4. Psychiatric or additive disorders that would preclude obtaining informed consent

          5. Serum bilirubin &gt; 1.5 times the upper limit of the normal range for the laboratory
             (ULN). Higher levels are acceptable if these are attributed to active hemolysis

          6. Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
             serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) levels &gt; 2
             times ULN

          7. Serum creatinine levels &gt; 1.5 times ULN

          8. Platelets &lt; 75,000/mm3

          9. Absolute neutrophil count &lt; 1500/mm3

         10. Active infection including viral hepatitis

         11. Known or suspected hypersensitivity to mannitol, azacitidine, or rituximab

         12. Grade 3 or 4 neuropathy

         13. Advanced hepatic tumors

         14. Uncompensated heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shams Shakil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lucille P. Markey Cancer Center at University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Shams Shakil</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

